Europe Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy, and Re

Europe Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy, and Research), and End-User (Hospitals and Clinics, Research and Academic Institutes, and Diagnostic Centers)

The Europe circulating tumor cell (CTC) diagnostics market is expected to reach US$ 957.8 million by 2028 from US$ 508.0 million in 2021; it is estimated to grow at a CAGR of 9.5% from 2021 to 2028.

Due to advancements in technologies related to feasibility and processing times, circulating tumor cell diagnostics and liquid biopsy have recently gathered considerable interest as a noninvasive alternative to tissue biopsy in cancer patients. The implementation of liquid biopsy procedures is supported by a greater understanding of improved minimally invasive cancer detection technologies. The market growth will be influenced by the rising demand for noninvasive tools, and laboratory acceptance of CTCs tests and liquid biopsy. A liquid biopsy allows doctors to obtain information about tumors from a simple blood sample. A blood test is painless, noninvasive, cost-effective, and less time-consuming. In addition, CTCs, cf DNAs, exosomes, and microvesicles can be detected in a blood sample, making blood-based liquid biopsies more popular.

The COVID-19 emergency has encouraged the general population to try out digital services and scale up their usage, particularly to avoid having to visit a health center in person. The unprecedented impact of COVID-19 has been far-reaching, but the effects on cancer patients make them one of the worst affected groups. COVID-19 has profoundly impacted the number of patients undergoing cancer screening, diagnosis, and treatment. The increased pressure due to the growing rate of COVID-19 patients' hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics, for accommodating the increasingly large number of COVID-19 patients. According to one study, many diagnostic and treatment procedures, including 2.3 million cancer surgeries, were canceled or postponed worldwide. Thus, the pandemic hindered the circulating tumor cell (CTC) diagnostics market growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market. The Europe circulating tumor cell (CTC) diagnostics market is expected to grow at a good CAGR during the forecast period.

Europe Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Europe Circulating Tumor Cell (CTC) Diagnostics Market Segmentation

By Technology

CTC detection and Enrichment Method CTC Direct Detection Methods CTC Analysis

By Application

Clinical/Liquid Biopsy Risk Assessment Screening and Monitoring Research Cancer Stem Cell and Tumorigenesis Research Drug/Therapy Development

By End-User

Hospitals and Clinics Research and Academic Institutes Diagnostic Centers

By Country

Germany UK France Spain Italy Rest of Europe

Companies Mentioned

Thermo Fisher Scientific Inc. Stemcell Technologies Inc. Qiagen Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation) Screencell Ikonisys, Inc Fluxion Biosciences

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe circulating tumor cell (CTC) diagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe circulating tumor cell (CTC) diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.